Loading...
Loading...
CBAY| Name | Value |
|---|---|
| Revenues | 31.0M |
| Cost of Revenue | 0.2M |
| Gross Profit | 30.8M |
| Operating Expense | 31.1M |
| Operating I/L | -0.1M |
| Other Income/Expense | -0.7M |
| Interest Income | 2.6M |
| Pretax | -0.8M |
| Income Tax Expense | 5.9M |
| Net Income/Loss | -0.8M |
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing therapies for liver and chronic diseases. Its lead product candidate, seladelpar (MBX-8025), is in phase III clinical study for primary biliary cholangitis (PBC) and has completed Phase 2b study for nonalcoholic steatohepatitis. The company also develops MBX-2982, in Phase 2a study for hypoglycemia in type 1 diabetics. CymaBay has a license agreement with ABW Cyclops SPV LP for seladelpar's development and a worldwide license from Janssen Pharmaceuticals, Inc. for compounds targeting an undisclosed metabolic disease. Its revenue is generated through the development and commercialization of these therapeutic products.
